目的 调查妇科肿瘤患者在化疗期间止吐药物的应用情况,为合理用药提供参考。方法 回顾性分析182例妇科肿瘤患者病例,并进行描述性统计分析和Logistic回归分析。结果 接受单日化疗的患者止吐药物使用的指南符合率为80%,接受多日化疗患者预防用药为95%,其中47%使用了5-HT3受体拮抗剂。结论 作为全国最大的肿瘤医院,预防性应用止吐药物的指南符合率高于以往研究结果。妇科肿瘤患者预防性应用止吐药物以5-HT3受体拮抗剂为主,联合应用地塞米松的止吐作用被忽视。
Abstract
OBJECTIVE To investigate the application of antiemetics in patients with gynecological cancers during chemotherapy.METHODS Medical records of 182 patients receiving chemotherapy for gynecological cancer were evaluated and a descriptive analysis was carried out. Logistic regression was performed to determine the predictors of compliance. RESULTS The rate of adherence to guideline (CINV) for patients receiving one-day chemotherapy is 80%. prophylactic usage rate in patients receiving multi-days chemotherapy is 95%, with a 47% 5-HT3 receptor antagonist. The adherence to NCCN anti-emesis guideline was better in patients having paclitaxel-based chemotherapy than patients having no paclitaxel.CONCLUSION As the biggest cancer hospital in China, antiemetics were commonly given as prevention of CINV in the form of 5-HT3 receptor antagonist, but antiemetic effect of dexamethasone was ignored and needed to be emphasized.
关键词
妇科肿瘤 /
止吐药 /
地塞米松 /
5-HT3受体拮抗剂
{{custom_keyword}} /
Key words
CINV /
gynecological cancer /
antiemetics /
dexamethasone /
5-HT3 receptor antagonist
{{custom_keyword}} /
中图分类号：
R969.3
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] FERNNDEZ-ORTEGA P, CALOTO M T, CHIRVECHES E, et al. Chemotherapy-induced nausea and vomiting in clinical practice: Impact on patients′ quality of life[J].Support Care Cancer, 2012,20(12): 3141-3148.
[2] ZHANG T T,LI Q. Neurokinin 1 receptor antagonist-a new choice to alleviate nausea and vomiting caused by chemotherapy[J]. Oncol Prog(癌症进展), 2013, 11(4):351-354.
[3] ZHANG X J, ZHANG P. Advances in mechanism and treatment of chemotherapy-induced nausea and vomiting[J].Oncol Prog(癌症进展), 2006, 4(4):348-354.
[4] HESKETH P J, AAPRO M, STREET J C, et al. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: Analysis of two phase Ⅲ trials of aprepitant in patients receiving cisplatin-based chemotherapy [J]. Support Care Cancer, 2010, 18(9):1171-1177.
[5] HESKETH P J. Defining the emetogenicity of cancer chemotherapy regimens: Relevance to clinical practice[J]. Oncologist, 1999, 4(3):191-196.
[6] SCHMOLL H J, JORDAN K, HUDDART R, et al.Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J].Ann Oncol, 2010, 21(suppl 5):140-146.
[7] WADDELL T, VERHEIJ M, ALLUM W, et al. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up[J].Eur J Surg Oncol, 2014, 40(5):584-591.
[8] LEDERMANN J A, RAJA F A, FOTOPOULOU C, et al.Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2013, 24(suppl 6):24-32.
[9] COLOMBO N, CARINELLI S, COLOMBO A, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, 23(suppl 7):27-32.
[10] BURMEISTER H L, AEBI S, STUDER C, et al. Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting[J]. Support Care Cancer, 2012, 20(1):141-147.
[11] NCCN Guideline(Version 2.2014)[S]. Antiemesis 2014.
[12] JIANG G, WANG Y X, ZHONG C Z, et al. Investigation of the application of antiemetic in the chemotherapy for 147 cases of non-small cell lung cancer[J]. J Cancer Control Treat, 2012, 25(4):230-232.
[13] LIU Y, ZHANG Y H. Analysis of the usage of glucocorticoid drugs in cancer hospital[J].China Pharm J(中国药学杂志), 2014, 49(3):250-252.
[14] TAN K, PAN B Y. Analysis of cost effect of docetaxel as first-line drug treatment for ovarian cancer[J]. China Pharm J(中国药学杂志), 2012, 47(11):870-871.
[15] MERTENS W C, HIGBY D J, BROWN D, et al. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: The effect of feedback to clinicians on adherence to antiemetic prescribing guidelines[J]. J Clin Oncol, 2003, 21(7):1373-1378.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(645 KB)
